Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncogene
Glavni autori: Sunaga, N, Kaira, K, Imai, H, Shimizu, K, Nakano, T, Shames, DS, Girard, L, Soh, J, Sato, M, Iwasaki, Y, Ishizuka, T, Gazdar, AF, Minna, JD, Mori, M
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451140/
https://ncbi.nlm.nih.gov/pubmed/22964644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2012.402
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items